Bioasis Technologies Inc., of Guilford, Conn., said it intends to complete a brokered private placement financing of units for gross proceeds of approximately $4 million. The company intends to use the net proceeds for manufacturing, IND-enabling studies and for general working capital purposes.
Biontech SE, of Mainz, Germany, said it filed a registration statement with the SEC to offer 13.2 million American depositary shares (ADSs) representing its ordinary shares to the public. The IPO price is expected to be between $18 and $20 per ADS, and the raise is expected to be approximately $250 million at the midpoint of the pricing range. Biontech also intends to grant the underwriters a 30-day option to purchase up to an additional 1.98 million ADSs. The company has applied to list its ADSs on Nasdaq under the symbol BNTX.
Ivexsol, of Boston, a viral vector manufacturing company, said it received $2 million in new convertible debt funding led by Casdin Capital LLC and Biolife Solutions. The company is founded on a next-generation manufacturing technology that revolutionizes the production of lentiviral vectors that have proved highly effective and safe for that purpose.
Provention Bio Inc., of Oldwick, N.J., said in connection with its follow-on financing and private placement, it generated total net proceeds of $62.7 million from an underwritten public offering of 5.75 million shares at $8 each, including the underwriters exercise of their overallotment option in full, as well as the issuance of 2.5 million shares at $8 each in a private placement with Amgen Inc., of Thousand Oaks, Calif. The net proceeds, together with its current cash position, are expected to fund the company's operations for the next two years.